Show simple item record

dc.contributor.authorLaurberg, T
dc.contributor.authorTramm, T
dc.contributor.authorNielsen, T
dc.contributor.authorAlsner, J
dc.contributor.authorNord, S
dc.contributor.authorMyhre, S
dc.contributor.authorSørlie, T
dc.contributor.authorLeung, S
dc.contributor.authorFan, C
dc.contributor.authorPerou, C
dc.contributor.authorGelmon, K
dc.contributor.authorOvergaard, J
dc.contributor.authorVoduc, D
dc.contributor.authorPrat, A
dc.contributor.authorCheang, MCU
dc.date.accessioned2018-01-26T09:27:08Z
dc.date.issued2018-01-01
dc.identifier.citationActa oncologica (Stockholm, Sweden), 2018, 57 (1), pp. 38 - 43
dc.identifier.issn0284-186X
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/1030
dc.identifier.eissn1651-226X
dc.identifier.doi10.1080/0284186x.2017.1401735
dc.description.abstractBACKGROUND: The study of the intrinsic molecular subtypes of breast cancer has revealed differences among them in terms of prognosis and response to chemotherapy and endocrine therapy. However, the ability of intrinsic subtypes to predict benefit from adjuvant radiotherapy has only been examined in few studies. METHODS: Gene expression-based intrinsic subtyping was performed in 228 breast tumors collected from two independent post-mastectomy clinical trials (British Columbia and the Danish Breast Cancer Cooperative Group 82b trials), where pre-menopausal patients with node-positive disease were randomized to adjuvant radiotherapy or not. All patients received adjuvant chemotherapy and a subgroup of patients underwent ovarian ablation. Tumors were classified into intrinsic subtypes: Luminal A, Luminal B, HER2-enriched, Basal-like and Normal-like using the research-based PAM50 classifier. RESULTS: In the British Columbia study, patients treated with radiation had an overall significant lower incidence of locoregional recurrence compared to the controls. For Luminal A tumors the risk of loco-regional recurrence was low and was further lowered by adjuvant radiation. These findings were validated in the DBCG 82b study. The individual data from the two cohorts were merged, the hazard ratio (HR) for loco-regional recurrence associated with giving radiation was 0.34 (0.19 to 0.61) overall and 0.12 (0.03 to 0.52) for Luminal A tumors. CONCLUSIONS: In both postmastectomy trials, patients with Luminal A tumors turned out to have a significant lower incidence of loco-regional recurrence when randomized to adjuvant radiotherapy, leaving no indication to omit postmastectomy adjuvant radiation in pre-menopausal high-risk patients with Luminal A tumors. It was not possible to evaluate the effect of radiotherapy among the other subtypes because of limited sample sizes.
dc.formatPrint-Electronic
dc.format.extent38 - 43
dc.languageeng
dc.language.isoeng
dc.publisherTAYLOR & FRANCIS LTD
dc.rights.urihttps://www.rioxx.net/licenses/under-embargo-all-rights-reserved
dc.subjectHumans
dc.subjectCarcinoma, Ductal, Breast
dc.subjectBreast Neoplasms
dc.subjectLymphatic Metastasis
dc.subjectNeoplasm Recurrence, Local
dc.subjectReceptor, erbB-2
dc.subjectReceptors, Estrogen
dc.subjectChemotherapy, Adjuvant
dc.subjectRadiotherapy, Adjuvant
dc.subjectDose Fractionation
dc.subjectLymph Node Excision
dc.subjectMastectomy
dc.subjectPremenopause
dc.subjectAdult
dc.subjectFemale
dc.titleIntrinsic subtypes and benefit from postmastectomy radiotherapy in node-positive premenopausal breast cancer patients who received adjuvant chemotherapy - results from two independent randomized trials.
dc.typeJournal Article
dcterms.dateAccepted2017-11-25
rioxxterms.versionofrecord10.1080/0284186x.2017.1401735
rioxxterms.licenseref.urihttps://www.rioxx.net/licenses/under-embargo-all-rights-reserved
rioxxterms.licenseref.startdate2018-01
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfActa oncologica (Stockholm, Sweden)
pubs.issue1
pubs.notesNo embargo
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Genomic Analysis – Clinical Trials
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Genomic Analysis – Clinical Trials
pubs.publication-statusPublished
pubs.volume57
pubs.embargo.termsNo embargo
icr.researchteamGenomic Analysis – Clinical Trials
dc.contributor.icrauthorCheang, Chon


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record